

RON JOHNSON, WISCONSIN, CHAIRMAN

JOHN MCCAIN, ARIZONA  
ROB PORTMAN, OHIO  
RAND PAUL, KENTUCKY  
JAMES LANKFORD, OKLAHOMA  
MICHAEL B. ENZI, WYOMING  
JOHN HOEVEN, NORTH DAKOTA  
STEVE DAINES, MONTANA

CLAIRE McCASKILL, MISSOURI  
THOMAS R. CARPER, DELAWARE  
HEIDI HEITKAMP, NORTH DAKOTA  
GARY C. PETERS, MICHIGAN  
MARGARET WOOD HASSAN, NEW HAMPSHIRE  
KAMALA D. HARRIS, CALIFORNIA  
DOUG JONES, ALABAMA

# United States Senate

COMMITTEE ON  
HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS

WASHINGTON, DC 20510-6250

May 16, 2018

The Honorable James Mattis  
Secretary  
Department of Defense  
1400 Defense Pentagon  
Washington, DC 20301

Dear Mr. Secretary:

I write to share information regarding Teva Pharmaceutical Industries, a contractor for the Department of Defense (DOD), which has arisen during my recent investigation into the U.S. opioid epidemic.

In July 2017, in my capacity as Ranking Member of the Senate Committee on Homeland Security and Governmental Affairs, I initiated an investigation into the role high-volume generic opioid manufacturers and distributors have played in fueling the current public health crisis. Over the course of several months, each of the distributors and two of the manufacturers provided documents and information in response to requests concerning their efforts to prevent opioid diversion. Teva, however, refused to provide information in response to my requests. Despite correspondence in which I noted that “the company’s decision to obstruct basic oversight on the opioid epidemic should deeply concern shareholders,”<sup>1</sup> Teva stated that a response could impact ongoing litigation and chill the willingness of its customers to address opioid abuse.<sup>2</sup>

As I noted in a public statement on March 6, 2018, “Teva’s refusal to cooperate with Congressional requests strongly suggests they have something to hide. I’d hope that everyone involved or associated with the company takes note that they’re dealing with an entity that’s stonewalling a Senate investigation examining a national public health crisis.”<sup>3</sup> This warning must also apply to DOD. Federal spending data indicates that DOD has awarded Teva Pharmaceutical Industries over \$8.5 million in contracts for its services in supplying various drugs and medical equipment since 2007.<sup>4</sup>

---

<sup>1</sup> Letter from Sen. Claire McCaskill to CEO Kåre Schultz (Sept. 28, 2017).

<sup>2</sup> Letter from Counsel for Teva to Sen. Claire McCaskill (Oct. 5, 2017).

<sup>3</sup> Sen. Claire McCaskill: *Teva is Stonewalling a Senate Investigation* (Mar. 6, 2018) ([www.mccaskill.senate.gov/media-center/news-releases/mccaskill-teva-is-stonewalling-a-senate-investigation](http://www.mccaskill.senate.gov/media-center/news-releases/mccaskill-teva-is-stonewalling-a-senate-investigation)).

<sup>4</sup> USA Spending database ([www.usaspending.gov](http://www.usaspending.gov)) (accessed Mar. 19, 2018).

The Honorable James Mattis  
May 16, 2018  
Page 2

I urge you to consider whether Teva's refusal to comply with my requests affects Teva's present responsibility as a government contractor. I also urge you to evaluate whether DOD should contract with an entity that has refused to respond to requests during a Senate investigation. As the Federal Acquisition Regulation states, federal contractors must "promote an organizational culture that encourages ethical conduct and a commitment to compliance with the law."<sup>5</sup> At the very least, the actions of Teva during my investigation—which has focused on one of the most pressing public health issues in the United States—should prompt a close look at existing financial relationships between the company and the federal government.

If you have any questions related to this request, please contact Brandon Reavis of my staff at (202) 224-2627. Please send any official correspondence related to this request to Rina Patel at [Rina\\_Patel@hsgac.senate.gov](mailto:Rina_Patel@hsgac.senate.gov). Thank you for your prompt attention to this matter.

Sincerely,



Claire McCaskill  
Ranking Member

cc: Ron Johnson  
Chairman

---

<sup>5</sup> FAR 52.203-13(b)(2).